Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Day One Biopharmaceuticals Inc (NQ: DAWN )

13.62 UNCHANGED
Streaming Delayed Price Updated: 1:46 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 474,230
Open 13.55
Bid (Size) 13.60 (7)
Ask (Size) 13.63 (7)
Prev. Close 13.62
Today's Range 13.30 - 13.70
52wk Range 11.30 - 18.07
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
-6.20%
-6.20%
1 Month
-8.77%
-8.77%
3 Month
-4.08%
-4.08%
6 Month
-6.84%
-6.84%
1 Year
+14.26%
+14.26%

More News

Read More
Why Carvana Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Day One Reports Third Quarter 2024 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Analyst Ratings for Day One Biopharmaceutical
Via Benzinga
Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Bank of America Says Buy These 3 Stocks for a Double-Digit Rally
Via InvestorPlace
Topics Economy
Exposures Economy
Meta To Rally Around 35%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
DAWN Stock Earnings: Day One Biopharmaceutical Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Day One Reports Second Quarter 2024 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Announces Oversubscribed $175.0 Million Private Placement
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Why Indivior Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Via Benzinga
Week In Review: FutureGen Sells mAb For IBD To AbbVie In $1.7 Billion Deal
Via Talk Markets
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Announces Sale of Priority Review Voucher for $108 Million
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
DAWN Stock Earnings: Day One Biopharmaceutical Misses EPS for Q1 2024
Via InvestorPlace
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Announces Two New Appointments to Board of Directors
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Dow Up Over 340 Points As Stocks Snap Back
Via Talk Markets
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.